Quarterly report pursuant to Section 13 or 15(d)

Accrued Liabilities and other Long-Term Liabilities

v3.19.1
Accrued Liabilities and other Long-Term Liabilities
3 Months Ended
Mar. 31, 2019
Payables and Accruals [Abstract]  
Accrued Liabilities and other Long-Term Liabilities
12. Accrued Liabilities and other Long-Term Liabilities
 
Accrued expenses and other long-term liabilities consisted of the following:
 
($ in thousands)
 
March 31,

2019
 
 
December

31, 2018
 
Accrued expenses:
 
 
 
 
 
 
 
 
Professional fees
 
$
1,262
 
 
$
1,434
 
Salaries, bonuses and related benefits
 
 
5,592
 
 
 
5,843
 
Accrued expenses - related party
 
 
16
 
 
 
 
Research and development
 
 
4,855
 
 
 
3,805
 
Research and development - milestones
 
 
 
 
 
200
 
Research and development - manufacturing
 
 
826
 
 
 
826
 
Research and development - clinical supplies
 
 
215
 
 
 
160
 
Research and development - license maintenance fees
 
 
489
 
 
 
519
 
Dr. Falk Pharma settlement
 
 
300
 
 
 
300
 
Accrued royalties payable
 
 
1,233
 
 
 
1,108
 
Accrued coupon expense
 
 
993
 
 
 
838
 
Other
 
 
4,546
 
 
 
1,327
 
Total accrued expenses
 
$
20,327
 
 
$
16,360
 
 
 
 
 
 
 
 
 
 
Other long-term liabilities:
 
 
 
 
 
 
 
 
Deferred expenses related to build-out
1
 
 
2,276
 
 
 
5,211
 
Total other long-term liabilities
 
$
2,276
 
 
$
5,211
 
 
Note 1: As of March 31, 2019, balance consists of deferred charges related to build-out of the New York facility, and as of December 31, 2018, balance consists of deferred rent and deferred build out charges.